Age-related and noise-induced hearing loss both involve NAD+ depletion in the cochlea. This article reviews the largely preclinical evidence on NMN and auditory protection, and is honest about how little human data exists.
NMN and Hearing Loss is a topic that sits at the intersection of aging biology and sensory neuroscience. As the global population ages, age-related hearing loss affects roughly one in three adults over 65. The emerging link between NAD+ decline and cochlear dysfunction offers a plausible mechanistic explanation—and raises the question of whether NMN supplementation could play a protective role.
Why the Cochlea Depends on NAD+
The cochlea is one of the most metabolically active tissues in the body. Its hair cells convert mechanical sound vibrations into electrical signals through a process that demands enormous amounts of ATP. This energy is supplied primarily by mitochondria, which require NAD+ (nicotinamide adenine dinucleotide) to function.
NAD+ serves two critical roles in cochlear health. First, it acts as an electron carrier in the mitochondrial electron transport chain, enabling oxidative phosphorylation. Second, it functions as a substrate for enzymes like PARPs (poly-ADP ribose polymerases) and sirtuins, which repair DNA damage and regulate cellular stress responses. Without adequate NAD+, both energy production and genomic maintenance in hair cells falter.
Gomes et al. (2013) demonstrated that declining NAD+ levels disrupt nuclear-mitochondrial communication, inducing what the authors termed a "pseudohypoxic state" during aging. This decline is not merely a biomarker—it is a mechanistic driver of cellular dysfunction across multiple tissues. The cochlea, with its high metabolic demand and limited regenerative capacity, is particularly vulnerable to this NAD+-dependent energy crisis.
The Evidence Base
Direct human trials examining NMN and hearing loss do not yet exist. The current evidence base consists of human studies on NMN safety and systemic NAD+ elevation, alongside mechanistic and animal research linking NAD+ metabolism to auditory function. This distinction matters: we cannot claim proven efficacy for hearing preservation in humans based on the available data.
| Study | Design | Population | Dose & Duration | Key Finding | Relevance to Hearing |
|---|---|---|---|---|---|
| Yoshino et al. (2021) | RCT | Prediabetic women (n=25) | 250 mg/day, 10 weeks | Improved muscle insulin sensitivity | Indirect—demonstrates tissue-level metabolic effects |
| Igarashi et al. (2022) | RCT | Healthy older men (n=21) | 250 mg/day, 12 weeks | Elevated blood NAD+ levels; altered muscle function | Indirect—confirms NAD+ elevation in older adults |
| Irie et al. (2020) | Open-label | Healthy Japanese men (n=10) | 100–500 mg/day, single dose to 5 weeks | Dose-dependent rise in blood NMN and NAD+ metabolites | Indirect—establishes pharmacokinetic profile |
| Liao et al. (2021) | RCT | Amateur runners (n=48) | 300–1200 mg/day, 6 weeks | Enhanced aerobic capacity at higher doses | Indirect—shows dose-dependent physiological effects |
| Niu et al. (2023) | RCT | Healthy adults, "pre-aging" (n=16) | 300 mg/day, 8 weeks | Altered serum metabolism; no significant telomere change | Indirect—metabolic effects in middle-aged adults |
| Gomes et al. (2013) | Preclinical | Mouse models | N/A (genetic/metabolic manipulation) | NAD+ decline drives pseudohypoxic state; reversible with supplementation | Direct mechanism—cochlear vulnerability implied by high metabolic demand |
None of these studies measured auditory outcomes. Yoshino et al. (2021) and Igarashi et al. (2022) focused on muscle metabolism in older adults. Irie et al. (2020) established that oral NMN raises blood metabolite levels in a dose-dependent fashion. Liao et al. (2021) demonstrated aerobic capacity improvements at doses up to 1200 mg/day. Niu et al. (2023) examined metabolic markers in a pre-aging cohort. The mechanistic foundation from Gomes et al. (2013) provides the biological rationale, but translation to human cochlear protection remains speculative.
The Mechanism: From NAD+ to Hair Cell Survival
Cochlear outer hair cells amplify sound vibrations through electromotility—a process driven by the motor protein prestin and fueled by ATP. Inner hair cells transduce these signals into glutamatergic neurotransmission to the auditory nerve. Both cell types are terminally differentiated neurons with minimal regenerative capacity in mammals.
NAD+ supports cochlear function through three interconnected pathways:
Mitochondrial Bioenergetics
Hair cells contain densely packed mitochondria, particularly at the cuticular plate and synaptic ribbon. NAD+ is the rate-limiting cofactor for complex I of the electron transport chain. When NAD+ declines, ATP production drops, calcium buffering fails, and synaptic transmission becomes unreliable. This energetic deficit mirrors the pattern described by Gomes et al. (2013) in systemic aging.
DNA Repair and Genomic Stability
Cochlear hair cells are exposed to chronic oxidative stress from both metabolic activity and acoustic trauma. PARP enzymes consume NAD+ to repair DNA strand breaks. Excessive PARP activation can deplete NAD+ pools, creating a vicious cycle of damage and energy failure. Sirtuins, particularly SIRT1 and SIRT3, also require NAD+ to deacetylate targets involved in mitochondrial biogenesis and antioxidant defense. For a deeper look at this repair machinery, see our article on NAD+ and DNA Repair: The PARP Connection Explained.
Sirtuin-Mediated Stress Resistance
SIRT3 localizes to mitochondria and regulates superoxide dismutase 2 (SOD2), a key antioxidant enzyme. NAD+-dependent sirtuin activity declines with age, reducing the cochlea's ability to neutralize reactive oxygen species generated during normal auditory function. This oxidative damage accumulates in hair cell stereocilia, synaptic ribbons, and spiral ganglion neurons.
The connection to mitochondrial health is explored further in NMN and Mitochondrial Function: The Energy Connection.
What the Evidence Does Not Show
It is essential to be clear about the limitations. No randomized controlled trial has tested whether NMN prevents, slows, or reverses hearing loss in humans. The studies by Yoshino et al. (2021), Igarashi et al. (2022), and Liao et al. (2021) examined metabolic and exercise outcomes—not auditory function. Irie et al. (2020) and Niu et al. (2023) focused on safety and biomarker changes.
Animal studies have shown more direct promise. Mouse models of noise-induced hearing loss and age-related hearing loss have demonstrated that NAD+ precursor supplementation can improve auditory brainstem response thresholds and reduce hair cell loss. However, these findings have not been replicated in human clinical trials. The gap between rodent cochlear biology and human auditory aging is substantial, involving differences in lifespan, frequency range, and etiological complexity.
Additionally, the optimal dose for cochlear NAD+ replenishment is unknown. Liao et al. (2021) used up to 1200 mg/day for aerobic capacity, while Yoshino et al. (2021) and Igarashi et al. (2022) used 250 mg/day for metabolic effects. Whether hearing-related benefits would require higher or lower doses, or different dosing schedules, remains entirely speculative.
Who Benefits Most
Based on the mechanistic rationale and the human safety data, certain populations may have stronger theoretical grounds for considering NMN supplementation in the context of auditory health:
Adults over 50 with early signs of hearing difficulty. NAD+ decline accelerates with age, and the cochlea is among the tissues most affected by this decline. How Fast Does NAD+ Decline With Age? The Data by Decade provides a detailed breakdown of this trajectory.
Individuals with occupational noise exposure. Chronic noise exposure depletes cochlear ATP and increases oxidative stress. While hearing protection remains the primary intervention, NAD+ support could theoretically augment cellular resilience.
Those with metabolic syndrome or insulin resistance. Yoshino et al. (2021) showed that NMN improves muscle insulin sensitivity in prediabetic women. Metabolic dysfunction and hearing loss share common pathways involving mitochondrial impairment and oxidative stress.
People with a family history of early-onset presbycusis. Genetic variants in mitochondrial DNA and NAD+ biosynthesis genes may increase susceptibility to age-related hearing loss, though this area requires more research.
Importantly, NMN is not a substitute for established hearing preservation strategies: limiting exposure to loud noise, using hearing protection, and seeking early audiological evaluation.
Practical Takeaways
- NMN raises blood NAD+ levels reliably in humans, as demonstrated by Irie et al. (2020) and Igarashi et al. (2022), but direct evidence for hearing benefits is absent.
- The cochlea's extreme metabolic dependence on NAD+ provides a plausible biological rationale for supplementation, supported by Gomes et al. (2013).
- Doses in human trials have ranged from 250 mg/day to 1200 mg/day, with no established optimal dose for auditory health. For those considering supplementation, Bio:sudo NMN 1000mg provides a dose within the range studied for physiological effects.
- NMN should be viewed as a potential adjunct to, not replacement for, standard hearing conservation practices.
- Individuals already experiencing hearing loss should consult an audiologist; NMN is not a proven treatment for existing impairment.
- Long-term safety data beyond 12 weeks is limited, though short-term studies report good tolerability.
Bottom Line
The connection between NMN and Hearing Loss is mechanistically compelling but clinically unproven. NAD+ decline is a genuine feature of cochlear aging, and NMN reliably elevates NAD+ in human subjects. However, no trial has yet tested whether this biochemical effect translates to preserved hearing function. For now, NMN remains a rational speculative intervention for auditory health—grounded in solid biology, but awaiting direct clinical validation.
References
- Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
- Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
- Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
- Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
- Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
- Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]
Try This Protocol
1,000 mg NMN · cGMP certified · COA available · third-party tested
Shop Now →